Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Agios Pharmaceuticals Q2 2024 GAAP EPS $(1.69) Misses $(1.60) Estimate, Sales $8.615M Miss $9.307M Estimate

Author: Benzinga Newsdesk | August 01, 2024 06:35am
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.60) by 5.62 percent. The company reported quarterly sales of $8.615 million which missed the analyst consensus estimate of $9.307 million by 7.44 percent. This is a 28.35 percent increase over sales of $6.712 million the same period last year.

Posted In: AGIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist